JournalFeed Logo

JournalFeed PubMetric Report

Analysis Source: PDF full text + PubMed metadata

JournalFeed PubMetric Score

11

High Confidence

PubMetric Score Breakdown

Relevance 2/2

Score 2 because the study addresses a common clinical scenario with potential for immediate application in practice.

Design & Methods 2/2

Score 2 because the study design is robust with appropriate randomization and control.

Bias Risk 1/2

Score 1 due to open-label design, which may introduce bias in outcome assessment.

Results 2/2

Score 2 because the results are statistically significant and clinically meaningful.

Certainty & Consistency 1/2

Score 1 due to limited sample size and single geographic location, affecting generalizability.

Applicability 1/2

Score 1 because the findings are applicable but require further validation in diverse populations.

Transparency 2/2

Score 2 because: Funding from Singhealth Medicine Academic Clinical Programme AND No conflicts declared.

Critical Appraisal

Title: Blood eosinophil-guided systemic corticosteroid duration in adults hospitalised for asthma exacerbation: a randomised, controlled, open-label, non-inferiority trial.
Background: Asthma exacerbations are a significant cause of morbidity and healthcare costs. Systemic corticosteroids are standard treatment, but optimal duration is unclear. Biomarker-guided approaches may reduce unnecessary exposure.
Study Question: Can blood eosinophil counts safely guide the reduction of systemic corticosteroid exposure in hospitalized asthma exacerbations?
Study Design: Randomized, controlled, open-label, noninferiority trial
Population: Adults aged ≥21 years hospitalized for asthma exacerbation, not on systemic corticosteroids within 7 days prior to admission
Intervention: Eosinophil-guided corticosteroid duration (3 days if eosinophils <300 cells/μL; 5 days if ≥300 cells/μL)
Comparison: Usual care with 5 days of prednisolone
Primary Outcome: Noninferiority of treatment failure rates (extension of steroid duration, mechanical ventilation, or death)
Secondary Outcomes: Length of stay, cumulative corticosteroid dose, additional steroid bursts, emergency visits, ACQ5 score changes
Key Statistics: Treatment failure rate difference of 3.6% (95% CI −8.9% to 16.2%), p=0.0004 for cumulative dose difference in noneosinophilic vs eosinophilic patients
Results: Eosinophil-guided therapy was noninferior to usual care with similar treatment failure rates and reduced steroid exposure in noneosinophilic patients.
Risk of Bias – RoB 2:
Randomization Process

Randomization was adequately performed with concealed allocation.

Deviations from Intended Interventions

Open-label design may have influenced treatment adherence and outcome assessment.

Missing Outcome Data

Follow-up was high with minimal missing data.

Measurement of the Outcome

Open-label design may have introduced bias in subjective outcome measures.

Selection of the Reported Result

All prespecified outcomes were reported.

Take Home: Blood eosinophil counts can guide corticosteroid duration in asthma exacerbations, reducing exposure without compromising safety.

JournalFeed Summary

Spoon Feed
Using blood eosinophil counts to guide corticosteroid duration in asthma exacerbations can reduce steroid exposure without compromising safety.

Eosinophil counts cut steroid use in asthma safely.
This randomized, open-label trial investigated whether blood eosinophil counts could guide the duration of systemic corticosteroid therapy in adults hospitalized for asthma exacerbations. Patients were randomized to either usual care (5 days of prednisolone) or eosinophil-guided care (3 days if eosinophils <300 cells/μL; 5 days if ≥300 cells/μL). The primary outcome was treatment failure, defined as the need for extended steroid duration, mechanical ventilation, or death. The study found that eosinophil-guided therapy was noninferior to usual care, with treatment failure rates of 10.9% in the eosinophil-guided group versus 7.3% in the usual care group. Importantly, noneosinophilic patients in the eosinophil-guided group received significantly lower cumulative steroid doses compared to eosinophilic patients (136 mg vs 214 mg, p=0.0004). Secondary outcomes, including length of stay and additional steroid bursts, showed no significant differences between groups.

How might this change our practice?
Consider using blood eosinophil counts to tailor corticosteroid duration in hospitalized asthma exacerbations to reduce unnecessary steroid exposure.

Source
Blood eosinophil-guided systemic corticosteroid duration in adults hospitalised for asthma exacerbation: a randomised, controlled, open-label, non-inferiority trial. . Thorax. 2025. PMID: 41339088